【摘要】 目的:探讨慢性乙型肝炎患者停用核苷(酸)类药物后的临床特征及影响因素。方法:收集73例慢性乙型肝炎患者停药后的临床资料,分析影响核苷(酸)类药物停药复发时间的因素。结果:拉米夫定组与联合用药组复发时间比较,患者复发时间较长(P=0.031)。在抗病毒疗程>24个月组,恩替卡韦与联合用药组复发时间比较,患者复发时间较长(P=0.048);拉米夫定组与恩替卡韦组复发时HBV DNA水平比较,恩替卡韦组患者HBV DNA水平较低(P=0.039)。在未达标患者中,抗病毒疗程是影响核苷(酸)类药物停药复发时间的危险因素。结论:大多数患者未达到停药标准而自行停药,已达到停药标准患者,停药后仍有较高复发率。在未达标患者中,抗病毒疗程长,与短时间内复发有关。更多还原

【Abstract】 Objective:To investigate the clinical features of chronic hepatitis B patients after stopping nucleos(t)ide analogues and related factors for hepatitis B relapse. Methods:We investigated 73 chronic hepatitis B patients who withdrew nucleos(t)ide analogues and analyzed the reasons for withdrawal and related factors for hepatitis B relapse. Results:Those who stopped lamivudine had longer relapse time compared with combination therapy(P=0.031). Among patients with total treatment duration more than 24 months,those who stopped entecavir had longer relapse time compared with combination therapy(P=0.048),and lower HBV DNA level while relapsed compared with lamivudine(P=0.039). The COX proportional hazards model analysis showed that total treatment duration was the risk factor for hepatitis B relapse after stopping nucleos(t)ide analogues with patients who did not achieve cessation criteria.Conclusion:Most patients stopped nucleos(t)ide analogues without achieving cessation criteria. There was a still high relapse rate among patients in spite of they had achieved cessation criteria. The longer antiviral treatment duration was associated with a short time recurrence with those who did not achieve cessation criteria.更多还原